Back to results
US 12,397,120 B2Granted
Systems and methods for mixing syringe valve assemblies
AssigneeTolmar International Limited
InventorsJames Sherman, Casey Dean, Carl Hart, John Bingham, Hossam Aboudagher
Life of this patent
Estimating the term…
Abstract
A syringe mixing system is provided for housing and mixing contents between at least two syringes. In some embodiments, a syringe coupler is provided that receives first and second syringes and includes a valve member that is convertible between a closed position and an open position. Retention systems for preventing or inhibiting removal of at least one syringe after use are also provided.
Claims26
A method of administering a Gonadotropin Releasing Hormone (GnRH) agonist to a subject for the treatment of prostate cancer or central precocious puberty (CPP), the method comprising:
- (i) providing, in a pre-assembled configuration, a syringe-to-syringe mixing system containing the Gonadotropin Releasing Hormone (GnRH) agonist, wherein the syringe-to-syringe mixing system comprises:
- a first syringe and a second syringe, each of the first syringe and the second syringe having a respective outlet, wherein the first syringe contains a liquid formulation component and the second syringe contains the Gonadotropin Releasing Hormone (GnRH) agonist;
- and
- a valve assembly comprising a displaceable member, a guide member, and a displaceable seal, wherein the outlets of the first and second syringes are coupled to the valve assembly, wherein the displaceable seal comprises a flow port extending through the displaceable seal, wherein the displaceable member is coupled to the displaceable seal and slidable relative to the guide member between a first position and a second position, wherein in the first position of the displaceable member, the flow port of the displaceable seal is offset from the outlet of at least one of the first syringe or the second syringe, wherein in the second position of the displaceable member, the flow port of the displaceable seal is aligned with the outlets of both the first syringe and the second syringe, and wherein the valve assembly further comprises a selectively rotatable member, wherein the selectively rotatable member receives a portion of the first syringe, wherein the displaceable member comprises at least one projection in communication with the selectively rotatable member when the displaceable member is in the first position, and wherein the at least one projection is spaced apart from the selectively rotatable member when the displaceable member is in the second position to permit free rotation of the selectively rotatable member;
- and
- (ii) administering the GnRH agonist to the subject using the syringe-to-syringe mixing system by:
- (a) positioning the displaceable member in the second position to form a fluid flow path extending through the flow port of the displaceable seal and between the outlet of the first syringe and the outlet of the second syringe;
- (b) mixing, through the fluid flow path, the liquid formulation component with the GnRH agonist to form a reconstituted pharmaceutical composition;
- and
- (c) administering the reconstituted pharmaceutical composition containing the GnRH agonist to the subject via subcutaneous injection, wherein administering the reconstituted pharmaceutical composition via subcutaneous injection comprises:
- with the reconstituted pharmaceutical composition received within the second syringe, disconnecting the second syringe from the valve assembly;
- and
- subcutaneously delivering, using the second syringe, the reconstituted pharmaceutical composition to the subject.
10 more elements
A method of administering a Gonadotropin Releasing Hormone (GnRH) agonist to a subject for the treatment of prostate cancer or central precocious puberty (CPP), the method comprising:
- (i) providing, in a pre-assembled configuration, a syringe-to-syringe mixing system containing the Gonadotropin Releasing Hormone (GnRH) agonist, wherein the syringe-to-syringe mixing system comprises:
- a first syringe and a second syringe, each of the first syringe and the second syringe having a respective outlet, wherein the first syringe contains a liquid formulation component and the second syringe contains the Gonadotropin Releasing Hormone (GnRH) agonist;
- and
- a valve assembly comprising a displaceable member, a guide member, and a displaceable seal, wherein the outlets of the first and second syringes are coupled to the valve assembly, wherein the displaceable seal comprises a flow port extending through the displaceable seal, wherein the displaceable member is coupled to the displaceable seal and slidable relative to the guide member between a first position and a second position, wherein in the first position of the displaceable member, the flow port of the displaceable seal is offset from the outlet of at least one of the first syringe or the second syringe, and wherein in the second position of the displaceable member, the flow port of the displaceable seal is aligned with the outlets of both the first syringe and the second syringe, wherein the displaceable member comprises at least one resilient projection, wherein the guide member comprises at least one recess that receives a corresponding resilient projection of the at least one resilient projection when the displaceable member is in the second position, wherein the at least one resilient projection is displaced upon movement of the displaceable member from the first position to the second position, and wherein engagement between the guide member and the at least one resilient projection prevents or inhibits the displaceable member from returning to the first position when the at least one resilient projection is received within the at least one recess of the guide member;
- and
- (ii) administering the GnRH agonist to the subject using the syringe-to-syringe mixing system by:
- (a) positioning the displaceable member in the second position to form a fluid flow path extending through the flow port of the displaceable seal and between the outlet of the first syringe and the outlet of the second syringe, wherein positioning the displaceable member in the second position comprises moving the displaceable member from the first position to the second position;
- (b) mixing, through the fluid flow path, the liquid formulation component with the GnRH agonist to form a reconstituted pharmaceutical composition;
- and
- (c) administering the reconstituted pharmaceutical composition containing the GnRH agonist to the subject via subcutaneous injection.
7 more elements
Dependencies are inferred from the claim text.